Woodcock, MDJanet Woodcock, MD, director of the Center for Drug Evaluation and Research at FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside
conference, November 12 to 14 in Washington D.C.
Another keynote speech, "Collaborative Networks as Tools for Improving Clinical Care," will be given by Pat Furlong, president and CEO of Parent Project Muscular Dystrophy
“We are thrilled by the incredible group of speakers who have agreed to share their expertise with us, and by the strong support that the PFF Summit 2015 is receiving from our community,” said Harold R. Collard, MD, chair of the Summit Education and Organizing Committee and a senior medical advisor at the Pulmonary Fibrosis Foundation
Related: Top 3 additions to IPF treatment guidelines
Other presentations at the PFF Summit include: “The Future of Clinical Trials in Pulmonary Fibrosis”, “Clinical Care: New and Evolving Treatment Strategies”, “Comprehensive Care – Beyond Pharmacological Therapies,” “Leveraging the PFF Care Center Network” and “Patient Perspective: Living Well with Pulmonary Fibrosis”.
In addition, a pre-conference patient and caregiver session will engage participants in a discussion about the importance of active participation by patients and caregivers in the management of pulmonary fibrosis, pulmonary rehab and oxygen therapy.
Related: Top 3 new findings on nintedanib to treat IPF
Two new luncheons have been added to this year’s conference. The Pulmonary Fibrosis Advocacy Workshop is designed to help participants learn the tools to effective advocacy and the Pulmonary Fibrosis Survey Session will reveal the results of a new survey on managing and living with PF.
To register for the PFF Summit 2015
, visit www.pffsummit.org
or call 888-733-6741.
Read more: 3 top concerns with IPF and comorbidities [SLIDESHOW]